#China #Shanghai #gastric cancer #CARsgen #Satri-cel

Introduction

The recent findings from CARsgen Therapeutics Holdings Limited have created considerable excitement in the oncology community at the 2026 ASCO Annual Meeting. Their novel autologous CAR T-cell therapy, referred to as satricabtagene autoleucel (satri-cel), has been presented as a viable sequential treatment following first-line therapy for patients grappling with advanced gastric and gastroesophageal junction adenocarcinoma (G/GEJA). This treatment shows potential in improving outcomes for patients whose survival prospects are particularly grim.

Study Overview

Presented on May 30, 2026, during the ASCO meeting, this research elaborates on the longitudinal results from an investigator-initiated clinical trial aimed at evaluating satri-cel's safety and efficacy. Satri-cel targets the protein Claudin18.2, showing promise not only for gastric cancers but potentially for other solid tumor types as well. The analysis focused on Cohort 3 of a phase 1 study, which included five patients, highlighting substantial follow-up results that exceeded 4.5 years.

Patient Details & Treatment

Out of the five patients enrolled, characteristics such as Lauren classification were noted, with a majority (60%) diagnosed with the diffuse type, known for its poor prognosis. Prior to the administration of satri-cel, these patients underwent a median of five cycles of first-line chemotherapy. The findings were stark: only one patient demonstrated a partial response to first-line therapy, underlining the need for alternative options in managing advanced G/GEJA.

Efficacy Results

The median follow-up duration was reported as 54.6 months as of October 18, 2025. Impressively, among patients with target lesions, the treatment yielded a 100% confirmed objective response rate, with patients experiencing durable responses. One patient maintained stable disease for over 20 months post-treatment. Furthermore, the median progression-free survival (PFS) was 20.9 months, indicating the potential for satri-cel to guide clinical benefits post-1L therapy. Notably, two patients who exhibited significant clinical improvement subsequently underwent surgical resections and continue to thrive long-term.

Safety Profile

The long-lasting follow-up also addresses safety aspects of the therapy. The results highlighted an encouraging safety profile for satri-cel, with no grade 3 or higher cytokine release syndrome (CRS) and no cases of immune effector cell-associated neurotoxicity syndrome (ICANS). Any occurrences of severe infections or treatment-related fatalities were notably absent, which is particularly reassuring for practitioners considering this therapy for high-risk populations.

Conclusion & Future Directions

These stellar findings support satri-cel's considerable promise as a sequential therapy for advanced G/GEJA. There’s also an ongoing momentum to broaden its application beyond gastric cancers into other domains like pancreatic cancer. As CARsgen continues to enhance the treatment landscape, the establishment of satri-cel's clinical value is imperative for future interventions and comprehensive cancer care strategies.

About CARsgen Therapeutics

CARsgen Therapeutics is dedicated to innovative CAR T-cell therapies aimed at fulfilling unmet clinical needs, focusing on hematologic malignancies and solid tumors. With a robust product pipeline, CARsgen aims to become a leading biopharmaceutical provider of transformative cell therapies for various cancer types. Through this aim, it strives to render many diseases curable and improve patient outcomes globally.